Heyuan Bio's Self-Developed Naji O仑赛 Injection (Yuanruida®) Listed in MIIT's First Batch of Iconic Biomanufacturing Products

List of Landmark Products in Biomanufacturing is issued by the Ministry of Industry and Information Technology of ChinaIn order to implement the spirit of the National New Industrialization Promotion Conference, promote the tackling of original and disruptive technologies and the application of landmark products, accelerate the transformation of innovative achievements into real productive forces, and enhance the integrated development capability of biomanufacturing "technology research and development - production - market promotion," based on relevant work arrangements and plans, and through procedures such as recommendations from provincial industrial and information technology authorities and expert reviews, a selection was formed. This time, 36 innovative products were selected for the first batch.List of Landmark Products in Biomanufacturing: Juventas' self-developed innovative drug product, Nageo-lun-cell Injection, which belongs to the biopharmaceutical field, is also the only CAR-T cell therapy innovative drug product selected.。

Since its establishment in 2018, Juventas has focused on core technological breakthroughs and industrialization in the field of cellular immunotherapy. It has grown into a leader of independent innovation in China's cell drug industry and is committed to becoming a world-leading next-generation biopharmaceutical enterprise driven by innovative cell and gene technologies. Juventas possesses full-process autonomous capabilities in R&D innovation, process development, production manufacturing, and commercialization. Globally, it has applied for over 90 patents and has been awarded the title of "National Intellectual Property Advantage Enterprise." The company has been approved to establish a national postdoctoral research workstation, selected for the National Key Research and Development Program by China’s Ministry of Science and Technology, and recognized as a specialized and innovative enterprise, a rising star in China's Greater Health Industry by Forbes China, and a notable emerging company in China's medical field by Hurun. Its independently developed core CAR-T product, Yuanruida®, was approved for marketing by the National Medical Products Administration in November 2023. It was recognized as one of "China’s Important Medical Advances of 2023" by the Chinese Academy of Medical Sciences and included in the "Top Ten Advances in China’s Pharmaceutical Biotechnology in 2023" by the China Association of Biotechnology, offering patients a breakthrough treatment option.

Dr. Lulu Lv, CEO of Juventas, stated:

Juventas' First Core Product, Yuanruida® (Najiolunsa Injection), Selected for the List of Iconic Biomanufacturing Products by China’s Ministry of Industry and Information Technology